Nevro is continuing to promote convincing clinical data to give it an edge in the increasingly competitive spinal cord stimulation (SCS) market.
Nevro’s HFX Offers Durable Benefit In People Suffering Diabetic Pain
New 24-month data from the SENZA-PDN trial, presented at the American Diabetes Society conference in New Orleans, provides more support for HFX 10 kHz as a reliable therapy for people with painful diabetic neuropathy.
